Abstract
In thoracic department of the National Cancer Institute studied the effectiveness of dendritic cell autovaccine in the postoperative period in non-small-cell lung cancer patients. The results, showing good tolerance dendritic cell autovaccine. Shows the formation of the expressed antigen immune response after repeated injections dendritic cell autovaccine, as manifested after 4 revaccination. Results of survival patients non-small-cell lung cancer who received postoperative dendritic cell autovaccines demonstrate the high efficiency of the method and its applicability with a minimum of side effects. Further study of survival of patients non-small-cell lung cancer who received immunotherapy treatment, monitoring of compliance with the best mode of repeated injections.
Publication types
-
English Abstract
-
Randomized Controlled Trial
MeSH terms
-
Aged
-
Antigen Presentation
-
Antigens, Neoplasm / immunology*
-
Cancer Vaccines / administration & dosage
-
Cancer Vaccines / immunology*
-
Carcinoma, Non-Small-Cell Lung / immunology
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Carcinoma, Non-Small-Cell Lung / therapy*
-
Cell Engineering
-
Cells, Cultured
-
Chemotherapy, Adjuvant
-
Cytotoxicity, Immunologic
-
Dendritic Cells / immunology
-
Dendritic Cells / transplantation*
-
Drug Administration Schedule
-
Female
-
Humans
-
Lung Neoplasms / immunology
-
Lung Neoplasms / mortality
-
Lung Neoplasms / pathology
-
Lung Neoplasms / therapy*
-
Male
-
Middle Aged
-
Survival Analysis
-
T-Lymphocytes, Cytotoxic / immunology
-
Vaccination
Substances
-
Antigens, Neoplasm
-
Cancer Vaccines